MIDDLE EAST & NORTH AFRICA

We supply globally branded pharmaceutical products as well as local brands into multiple territories within Middle East and North Africa (“MENA”). Egypt, Algeria and Saudi Arabia combined contributed approximately 50% to total sales in MENA for the 2018 financial year.

Key Countries

Algeria
Egypt
Morocco
Saudi Arabia
United Arab Emirates

Contribution to Group revenue

Revenue contribution - by therapeutic category

The MENA pharmaceutical sector was valued at USD26,0 billion as at 30 June 2018.
The top nine major markets (which include, inter alia, the Kingdom of Saudi Arabia, Algeria, Egypt and the United Arab Emirates) were value at USD17,4 billion and grew 9,3%.

Source: June 2018 IMS

STATISTICS

Number of products launched:

8

(2017: 2)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:

0 – 2 years

USD160 million

3 – 5 years

USD3 million

Number of product recalls:

Nil

(2017: nil)

Average staff turnover:

10,9%

(2016: 18,2%)

Number of work-related fatalities:

Nil

(2017: nil)

Number of permanent employees:

Revenue – R’billion	2018	2017 (CER)	% change
Total	877	1 049	(16)
Regional Brands	369	413	(11)
Anaesthetics	156	228	(32)
Thrombosis	159	166	(4)
High Potency & Cytotoxics	193	242	(20)